Trial Profile
Randomized Phase II Trial Seeking the Most Promising Drug Association With Azacitidine- in Higher Risk Myelodysplastic Syndromes.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Idarubicin (Primary) ; Lenalidomide (Primary) ; Valproic acid (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- Acronyms AZA-PLUS
- Sponsors Assistance Publique Hopitaux de Paris
- 18 Feb 2019 Planned End Date changed from 1 Jan 2019 to 1 Jun 2019.
- 04 Dec 2018 Primary endpoint (Remission, complete, partial or medullary after 6 cycles) has not been met, according to the results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology